Ergocalciferol in Chronic Kidney Disease

This study has been completed.
Information provided by:
Saint Louis VA Medical Center Identifier:
First received: December 11, 2006
Last updated: NA
Last verified: December 2006
History: No changes posted

To examine the effect of ergocalciferol treatment on 25-hydroxyvitamin D and PTH levels in patients with CKD stage 3 and 4

Chronic Kidney Disease

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Official Title: The Effect of Ergocalciferol Treatment on 25-Hydroxyvitamin D Levels and Plasma Intact PTH in Patients With Chronic Kidney Disease Stage 3 and 4

Resource links provided by NLM:

Further study details as provided by Saint Louis VA Medical Center:


Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient with CKD stage 3 or 4 whose 25-hydroxyvitamin D levels are below 30 ng/ml and plasma intact PTH levels >70 pg/ml.

Exclusion Criteria:

  • Patients who are on any form of active vitamin treatment
  Contacts and Locations
Please refer to this study by its identifier: NCT00411294

United States, Missouri
Saint Louis VA Medical Center
Saint Louis, Missouri, United States, 63104
Sponsors and Collaborators
Saint Louis VA Medical Center
Principal Investigator: Ziyad Al-Aly, M.D. VAMC-Saint Louis
  More Information

No publications provided by Saint Louis VA Medical Center

Additional publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00411294     History of Changes
Other Study ID Numbers: ZA-01
Study First Received: December 11, 2006
Last Updated: December 11, 2006
Health Authority: United States: Federal Government

Keywords provided by Saint Louis VA Medical Center:
chronic kidney disease
secondary hyperparathyroidism
vitamin D deficiency

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Kidney Failure, Chronic
Urologic Diseases
Renal Insufficiency
Vitamin D
Bone Density Conservation Agents
Physiological Effects of Drugs
Pharmacologic Actions
Growth Substances processed this record on April 15, 2014